We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Consensus Estimate for DHR’s second-quarter earnings has been revised downward by 5.2% in the past 90 days. However, the company has an impressive earnings surprise history, having outperformed the Zacks Consensus Estimate in each of the trailing four quarters, the average beat being 11%.
Let’s see how things are shaping up for Danaher this earnings season.
Healthy demand for bioprocessing products is expected to have aided Danaher’s Life Sciences segment. The Zacks Consensus Estimate for Life Sciences segment’s total sales in the second quarter indicates a 4% increase from the year-ago reported figure.
The Diagnostics segment revenues are likely to have been driven by healthy demand for products related to molecular testing and higher non-COVID testing volumes. Healthy consumables business and solid demand for equipment areexpected to have boosted revenues of the Environmental & Applied Solutions segment. The Zacks Consensus Estimate for second-quarter Environmental & Applied Solutions’ total sales hints at a 1.4% rise from the second-quarter 2021 reported figure.
Danaher expects year-over-year core revenue growth in the range of low-single digits for the second quarter. The company expects the impact of COVID-related testing to have boosted sales in the low-single digits in the to-be-reported quarter.
However, inflationary pressure and supply chain woes might have impacted Danaher’s margin performance in the second quarter. High cost of sales, selling, general and administrative expenses and research and development expenses might have impeded DHR’s bottom-line performance.
What Does the Zacks Model Say?
Our proven model does not conclusively predict an earnings beat for Danaher this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of beating estimates, which is not the case here, as elaborated below. You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings ESP: Danaher has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at $2.36. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Danaher carries a Zacks Rank #3.
Highlights of Q1 Earnings
Danaher’s first-quarter adjusted earnings of $2.76 per share surpassed the Zacks Consensus Estimate of $2.65. The bottom line increased 9.5% from the year-ago quarter’s figure of $2.52, primarily on sales growth. The company’s net sales of $7,688 million surpassed the Zacks Consensus Estimate of $7,546 million. Solid segmental performances boosted DHR’s top line on a year-over-year basis.
Stocks to Consider
Here are some companies that you may want to consider as, according to our model, these have the right combination of elements to beat on earnings in this reporting cycle.
Crane Holdings (CR - Free Report) has an Earnings ESP of +6.98% and a Zacks Rank #2. The company is slated to release second-quarter 2022 financial numbers on Jul 25.
Crane Holdings’ earnings have surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average beat being 22.2%.
Zebra Technologies (ZBRA - Free Report) has an Earnings ESP of +2.15% and a Zacks Rank #3. The company is scheduled to release second-quarter 2022 earnings numbers on Aug 2.
Zebra Technologies’ earnings have trumped the Zacks Consensus Estimate in each of the trailing four quarters, the average beat being 8.8%.
Image: Shutterstock
Will Cost Headwinds Dampen Danaher's (DHR) Q2 Earnings?
Danaher Corporation (DHR - Free Report) is scheduled to release second-quarter 2022 earnings numbers on Jul 21, before market open.
The Zacks Consensus Estimate for DHR’s second-quarter earnings has been revised downward by 5.2% in the past 90 days. However, the company has an impressive earnings surprise history, having outperformed the Zacks Consensus Estimate in each of the trailing four quarters, the average beat being 11%.
Let’s see how things are shaping up for Danaher this earnings season.
Danaher Corporation Price and EPS Surprise
Danaher Corporation price-eps-surprise | Danaher Corporation Quote
Factors to Note
Healthy demand for bioprocessing products is expected to have aided Danaher’s Life Sciences segment. The Zacks Consensus Estimate for Life Sciences segment’s total sales in the second quarter indicates a 4% increase from the year-ago reported figure.
The Diagnostics segment revenues are likely to have been driven by healthy demand for products related to molecular testing and higher non-COVID testing volumes. Healthy consumables business and solid demand for equipment areexpected to have boosted revenues of the Environmental & Applied Solutions segment. The Zacks Consensus Estimate for second-quarter Environmental & Applied Solutions’ total sales hints at a 1.4% rise from the second-quarter 2021 reported figure.
Danaher expects year-over-year core revenue growth in the range of low-single digits for the second quarter. The company expects the impact of COVID-related testing to have boosted sales in the low-single digits in the to-be-reported quarter.
However, inflationary pressure and supply chain woes might have impacted Danaher’s margin performance in the second quarter. High cost of sales, selling, general and administrative expenses and research and development expenses might have impeded DHR’s bottom-line performance.
What Does the Zacks Model Say?
Our proven model does not conclusively predict an earnings beat for Danaher this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of beating estimates, which is not the case here, as elaborated below. You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings ESP: Danaher has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at $2.36. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Danaher carries a Zacks Rank #3.
Highlights of Q1 Earnings
Danaher’s first-quarter adjusted earnings of $2.76 per share surpassed the Zacks Consensus Estimate of $2.65. The bottom line increased 9.5% from the year-ago quarter’s figure of $2.52, primarily on sales growth. The company’s net sales of $7,688 million surpassed the Zacks Consensus Estimate of $7,546 million. Solid segmental performances boosted DHR’s top line on a year-over-year basis.
Stocks to Consider
Here are some companies that you may want to consider as, according to our model, these have the right combination of elements to beat on earnings in this reporting cycle.
Crane Holdings (CR - Free Report) has an Earnings ESP of +6.98% and a Zacks Rank #2. The company is slated to release second-quarter 2022 financial numbers on Jul 25.
Crane Holdings’ earnings have surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average beat being 22.2%.
Zebra Technologies (ZBRA - Free Report) has an Earnings ESP of +2.15% and a Zacks Rank #3. The company is scheduled to release second-quarter 2022 earnings numbers on Aug 2.
Zebra Technologies’ earnings have trumped the Zacks Consensus Estimate in each of the trailing four quarters, the average beat being 8.8%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.